Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases
ConditionCardiovascular Diseases (CVD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai East Hospital
About this trial
FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.
Eligibility criteria
Qualifiers
Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings.
Age requirement: >18 years.
Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period.
Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures.
Disqualifiers
History of malignancy
Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions
Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses
Claustrophobia
Trial design
Treatments tested in this trial
- Not listed
Trial groups
40 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov